Complement is crucial for host defense but may also drive dysregulated inflammation. There is limited understanding of alternative complement function, which can amplify all complement activity, during critical illness. We examined the function and key components of the alternative complement pathway in a series of critically ill patients and in a mouse pneumonia model. Total classical (CH50) and alternative complement (AH50) function were quantified in serum from 321 prospectively enrolled critically ill patients and compared with clinical outcomes. Alternative pathway (AP) regulatory factors were quantified by ELISA ( = 181) and examined via transcriptomics data from external cohorts. Wild-type, , and mice were infected intratracheally with (KP) and assessed for extrapulmonary dissemination. AH50 greater than or equal to median, but not CH50 greater than or equal to median, was associated with decreased 30-day mortality (adjusted odds ratio [OR], 0.53 [95% confidence interval (CI), 0.31-0.91]), independent of chronic liver disease. One-year survival was improved in patients with AH50 greater than or equal to median (adjusted hazard ratio = 0.59 [95% CI, 0.41-0.87]). Patients with elevated AH50 had increased levels of AP factors B, H, and properdin, and fewer showed a "hyperinflammatory" subphenotype (OR, 0.30 [95% CI, 0.18-0.49]). Increased expression of proximal AP genes was associated with improved survival in two external cohorts. AH50 greater than or equal to median was associated with fewer bloodstream infections (OR, 0.67 [95% CI, 0.45-0.98). Conversely, depletion of AP factors, or AH50 less than median, impaired serum control of KP that was restored by adding healthy serum. mice demonstrated increased extrapulmonary dissemination and serum inflammatory markers after intratracheal KP infection compared with wild type. Elevated AP function is associated with improved survival during critical illness, possibly because of enhanced immune capacity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365364 | PMC |
http://dx.doi.org/10.1164/rccm.201910-2083OC | DOI Listing |
Sci Rep
January 2025
Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, No.1 East Jianshe Road, Erqi District, Zhengzhou, 450052, China.
Increasing evidence points toward an essential role for complement activation in the pathogenesis of diabetic kidney disease (DKD). However, the precise molecular mechanisms remain unclear, and the pathway predominantly contributing to complement activation in DKD is of particular interest. In this study, the glomerular proteome, especially the profiles of the complement proteins, was analyzed in kidney biopsies from 40 DKD patients and 10 normal controls using laser microdissection-assisted liquid chromatography-tandem mass spectrometry (LMD-LC-MS/MS).
View Article and Find Full Text PDFBackground: Extracellular vesicles (EVs) carry pathogenic molecules and play a role in the disease spread, including aggregated tau proteins. The Endosomal Sorting Complexes Required for Transport (ESCRT) machinery is responsible for the biogenesis of small EVs (exosomes), thus targeting critical ESCRT molecules can disrupt EV synthesis. We hypothesize that microglia-specific targeting of ESCRT-I molecule Tsg101 suppresses microglia-derived EV-mediated propagation of tau pathology, leading to amelioration of the disease phenotype of the tauopathy mouse model.
View Article and Find Full Text PDFJ Complement Integr Med
January 2025
International College of Apitherapy, Bogota, Colombia.
Introduction: Diabetes mellitus is a complex disease in terms of its causes and pathophysiological processes, it produces a significant impact on health and leads to complications that are difficult to manage.
Content: This review summarizes and analyzes recent advances in the understanding of the mechanisms of diabetes mellitus and how apitherapy affects them. Also present the available clinical evidence on its application.
Complement Ther Med
December 2024
Department of Operating Room Nursing, Abadan University of Medical Sciences, Abadan, Iran. Electronic address:
Med J Armed Forces India
December 2024
Senior Advisor (Medicine) & Nephrologist, Base Hospital Delhi Cantt, New Delhi, India.
The SARS-CoV-2 virus can cause thrombotic microangiopathy (TMA) by alternate pathway activation. We present a case of a young female patient who presented with fever and dialysis-dependent acute kidney injury. On evaluation, she was diagnosed with COVID-19-induced complement-mediated thrombotic microangiopathy (CM-TMA).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!